🇺🇸 FDA
Patent

US 10786461

Onapristone extended-release compositions and methods

granted A61KA61K31/575A61K9/20

Quick answer

US patent 10786461 (Onapristone extended-release compositions and methods) held by CONTEXT BIOPHARMA, INC. expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CONTEXT BIOPHARMA, INC.
Grant date
Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/575, A61K9/20, A61K9/2054, A61P